AVBP ArriVent BioPharma, Inc.companySEC Filings & Insider Trading Activity 2026
Latest ArriVent BioPharma, Inc. (AVBP) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 5, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 17, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ArriVent BioPharma, Inc. (AVBP) (SEC CIK 1868279), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • ArriVent BioPharma (AVBP) issued a press release containing material information disclosed under Item 8.01
- • Full details available in the referenced exhibit — filing text itself contains no disclosed figures or event specifics
Item 7.01: Regulation FD Disclosure
- • Firmonertinib (EGFR inhibitor) and ARR-002 (MUC16/NaPi2b tetravalent ADC) preclinical data to be presented at 2026 AACR Annual Meeting
- • ARR-002 is a novel dual-target ADC — early pipeline asset; AACR presentation marks first public preclinical data disclosure
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1)
- • Reporting period: fiscal year ended December 31, 2025
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ArriVent BioPharma, Inc. (AVBP) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 17, 2026 | — | Analysis | — |
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Mar 5, 2026 | Dec 31, 2025 | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 3, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 14, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — |
Frequently Asked Questions
What are the latest AVBP SEC filings in 2026?
ArriVent BioPharma, Inc. (AVBP) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did AVBP file its most recent 10-K annual report?
ArriVent BioPharma, Inc. (AVBP) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view AVBP 10-Q quarterly reports?
ArriVent BioPharma, Inc. (AVBP)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every AVBP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has AVBP filed recently?
ArriVent BioPharma, Inc. (AVBP)'s most recent 8-K was filed on March 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find AVBP insider trading activity (Form 4)?
SignalX aggregates every AVBP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does AVBP file with the SEC?
ArriVent BioPharma, Inc. (AVBP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AVBP filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ArriVent BioPharma, Inc. (AVBP).
What is AVBP's SEC CIK number?
ArriVent BioPharma, Inc. (AVBP)'s SEC CIK (Central Index Key) number is 1868279. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1868279 to look up all AVBP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find AVBP return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ArriVent BioPharma, Inc. (AVBP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ArriVent BioPharma, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 11+ filings.